Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)

Completed · Phase 2

Conditions studied: Diabetic Macular Edema

In brief

This is an open-label study evaluating the safety and tolerability of topical ocular mecamylamine given twice a day in patients with diabetic macular edema (DME). Patients will be treated for 12 weeks.

Key facts

Study ID

NCT00536692

Run by

CoMentis

Starts

2007-09-01

Expected to finish

2008-04-01

Last updated by the study team

2008-04-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• macular edema due to diabetic retinopathy

You may not qualify if…

• vision loss from other ocular disease
• intraocular surgery within 3 months
• intraocular anti-VEGF or steroids within 3 months
• HbA1c >12

Where it is running

• East Bay Retina Consultants, Inc. — Oakland, California, United States
• Johns Hopkins School of Medicine / Wilmer Eye Institute — Baltimore, Maryland, United States
• Ophthalmic Consultants of Boston — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.